OTCMKTS:BSPM Biostar Pharmaceuticals (BSPM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Biostar Pharmaceuticals Stock (OTCMKTS:BSPM) Get BSPM alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Biostar Pharmaceuticals, Inc. (OTCMKTS: BSPM) is a development-stage biopharmaceutical company focused on acquiring, licensing and advancing novel therapeutic candidates in oncology and metabolic disease. The company’s primary business activity involves identifying proprietary small-molecule and biologic compounds through collaborations with academic institutions, research organizations and biotech partners. Biostar aims to leverage cost-effective development pathways to progress its pipeline from preclinical research into early-stage clinical trials. Through strategic licensing agreements, Biostar Pharmaceuticals builds a diversified portfolio of drug candidates targeting solid tumors, hematological malignancies and metabolic disorders. The company’s R&D strategy emphasizes preclinical validation, pharmacology studies and formulation development, with the goal of advancing select assets toward Phase 1 and Phase 2 clinical evaluations. By focusing on niche indications and leveraging external expertise, Biostar seeks to optimize capital efficiency and position its programs for potential out-licensing or co-development partnerships. Biostar serves global markets via collaborative networks rather than direct commercial operations, enabling the company to tap into specialized research capabilities and manufacturing resources worldwide. While specific leadership details are not broadly publicized, the management team comprises professionals with backgrounds in drug discovery, regulatory affairs and business development. Biostar continues to explore new licensing opportunities and strategic alliances to expand its pipeline and move its therapeutic programs forward.AI Generated. May Contain Errors. Read More Receive BSPM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biostar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSPM Stock News HeadlinesBeijing Biostar Pharmaceuticals Co. Ltd.April 5, 2026 | wsj.comBiostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)September 15, 2025 | finance.yahoo.comEx-CIA Insider: “Prepare for a Mid-Term Meltdown”Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election, and the Covid crisis - is now warning investors to prepare for a historic mid-term meltdown. Rickards outlines three specific steps he says everyday investors should take before things turn ugly. Those who act early may avoid the losses that could wipe out millions of unprepared portfolios.July 18 at 1:00 AM | Paradigm Press (Ad)Biostar Pharmaceuticals Inc (BSPM)April 24, 2025 | nasdaq.comBiostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer DrugJune 12, 2023 | benzinga.comBioCryst Pharmaceuticals Stock Down 20% After Wider 4Q Loss ReportedFebruary 23, 2023 | marketwatch.comBiostar Pharmaceuticals, Inc. (BSPM)August 14, 2022 | finance.yahoo.comBiostar launches new mining rig with 8 graphics cardsApril 28, 2022 | msn.comSee More Headlines BSPM Stock Analysis - Frequently Asked Questions How were Biostar Pharmaceuticals' earnings last quarter? Biostar Pharmaceuticals, Inc. (OTCMKTS:BSPM) announced its quarterly earnings data on Wednesday, November, 15th. The company reported ($0.50) EPS for the quarter. How do I buy shares of Biostar Pharmaceuticals? Shares of BSPM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biostar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biostar Pharmaceuticals investors own include Cellectar Biosciences (CLRB), HudBay Minerals (HBM), Baytex Energy (BTE), Cyclacel Pharmaceuticals (CYCC) and Company Calendar Last Earnings11/15/2017Today7/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BSPM CIKN/A Webbiostarpharmaceuticals.com Phone862933686638FaxN/AEmployees200Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta71.78 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:BSPM) was last updated on 7/18/2026 by MarketBeat.com Staff. From Our PartnersCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredEx-CIA Insider: “Prepare for a Mid-Term Meltdown”Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...Paradigm Press | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biostar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biostar Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.